NASDAQ:OSUR - OraSure Technologies Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $16.93 +0.02 (+0.12 %) (As of 07/23/2018 06:00 AM ET)Previous Close$16.93Today's Range$16.69 - $17.0452-Week Range$12.86 - $23.01Volume388,733 shsAverage Volume465,181 shsMarket Capitalization$1.03 billionP/E Ratio33.20Dividend YieldN/ABeta1.63 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV?1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, OMNIgene DISCOVER, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, GenoFIND, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and consumers. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania. Receive OSUR News and Ratings via Email Sign-up to receive the latest news and ratings for OSUR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical SymbolNASDAQ:OSUR CUSIP68554V10 Webwww.orasure.com Phone610-882-1820 Debt Debt-to-Equity RatioN/A Current Ratio9.29 Quick Ratio8.30 Price-To-Earnings Trailing P/E Ratio33.20 Forward P/E Ratio52.91 P/E Growth4.23 Sales & Book Value Annual Sales$167.06 million Price / Sales6.19 Cash Flow$0.6159 per share Price / Cash27.49 Book Value$4.26 per share Price / Book3.97 Profitability EPS (Most Recent Fiscal Year)$0.51 Net Income$30.94 million Net Margins9.28% Return on Equity6.58% Return on Assets5.84% Miscellaneous Employees377 Outstanding Shares61,060,000Market Cap$1,033.81 OraSure Technologies (NASDAQ:OSUR) Frequently Asked Questions What is OraSure Technologies' stock symbol? OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR." How were OraSure Technologies' earnings last quarter? OraSure Technologies, Inc. (NASDAQ:OSUR) posted its earnings results on Wednesday, May, 2nd. The medical instruments supplier reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.06) by $0.03. The medical instruments supplier earned $41.99 million during the quarter, compared to the consensus estimate of $40.53 million. OraSure Technologies had a return on equity of 6.58% and a net margin of 9.28%. The business's quarterly revenue was up 29.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.21 EPS. View OraSure Technologies' Earnings History. When is OraSure Technologies' next earnings date? OraSure Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for OraSure Technologies. What price target have analysts set for OSUR? 3 Wall Street analysts have issued twelve-month price objectives for OraSure Technologies' shares. Their predictions range from $23.00 to $24.00. On average, they expect OraSure Technologies' stock price to reach $23.50 in the next twelve months. This suggests a possible upside of 38.8% from the stock's current price. View Analyst Ratings for OraSure Technologies. What is the consensus analysts' recommendation for OraSure Technologies? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." Who are some of OraSure Technologies' key competitors? Some companies that are related to OraSure Technologies include Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Nevro (NVRO), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Cardiovascular Systems (CSII), Atrion (ATRI), Orthofix International (OFIX), Cryolife (CRY) and AtriCure (ATRC). Who are OraSure Technologies' key executives? OraSure Technologies' management team includes the folowing people: Dr. Stephen S. Tang, Pres, CEO & Director (Age 57)Mr. Jack E. Jerrett, Sr. VP, Gen. Counsel & Sec. (Age 59)Mr. Anthony Zezzo II, Exec. VP & Bus. Unit Leader of Infectious Disease (Age 64)Mr. Brian L. Smith, Exec. VP & Bus. Unit Leader of Molecular Solutions - DNA Genotek, Inc. (Age 59)Mr. Roberto E. Cuca, Chief Financial Officer (Age 50) Has OraSure Technologies been receiving favorable news coverage? News stories about OSUR stock have trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OraSure Technologies earned a daily sentiment score of 0.10 on Accern's scale. They also gave media coverage about the medical instruments supplier an impact score of 46.92 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. Who are OraSure Technologies' major shareholders? OraSure Technologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fred Alger Management Inc. (4.41%), Peregrine Capital Management LLC (1.72%), Fisher Asset Management LLC (0.65%), Sicart Associates LLC (0.39%), American Capital Management Inc. (0.33%) and Bank of Montreal Can (0.15%). Company insiders that own OraSure Technologies stock include Anthony Zezzo II, Brian Smith, Charles W Patrick, Douglas A Michels, Jack E Jerrett, Mara G Aspinall, Mark L Kuna, Michael Celano, Ronald H Spair, Ronny B Lancaster and Stephen S Phd Tang. View Institutional Ownership Trends for OraSure Technologies. Which institutional investors are selling OraSure Technologies stock? OSUR stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Municipal Employees Retirement System of Michigan, Bank of Montreal Can and Sicart Associates LLC. Company insiders that have sold OraSure Technologies company stock in the last year include Anthony Zezzo II, Brian Smith, Charles W Patrick, Douglas A Michels, Jack E Jerrett, Ronald H Spair and Stephen S Phd Tang. View Insider Buying and Selling for OraSure Technologies. Which institutional investors are buying OraSure Technologies stock? OSUR stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., American Capital Management Inc., Peregrine Capital Management LLC and Xact Kapitalforvaltning AB. View Insider Buying and Selling for OraSure Technologies. How do I buy shares of OraSure Technologies? Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is OraSure Technologies' stock price today? One share of OSUR stock can currently be purchased for approximately $16.93. How big of a company is OraSure Technologies? OraSure Technologies has a market capitalization of $1.03 billion and generates $167.06 million in revenue each year. The medical instruments supplier earns $30.94 million in net income (profit) each year or $0.51 on an earnings per share basis. OraSure Technologies employs 377 workers across the globe. How can I contact OraSure Technologies? OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected] MarketBeat Community Rating for OraSure Technologies (NASDAQ OSUR)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 406 (Vote Outperform)Underperform Votes: 244 (Vote Underperform)Total Votes: 650MarketBeat's community ratings are surveys of what our community members think about OraSure Technologies and other stocks. Vote "Outperform" if you believe OSUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSUR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/23/2018 by MarketBeat.com StaffFeatured Article: What does relative strength index mean?